New website serves REMS writers

Consultancy BioTrak Market Intelligence has launched REMSadvisor.com, a resource for those developing risk evaluation and mitigation strategies. REMS have become an increasingly required approval component for drugs that the FDA deems to have safety risks.

The Internet site addresses program design, implementation, and assessment, which BioTrak says have been challenging for drugmakers. Content includes methods, guidance, and REMS experiences, some related via video presentations.

The FDA last fall issued draft guidance on REMS format and content, a blueprint for manufacturers developing the safety strategies intended to ensure drug benefits outweigh risks.

REMS are on the rise. The FDA recently required them for erythropoiesis-stimulating agents, setting three manufacturers to the task.

- here's the announcement

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.